MONECO Advisors LLC Buys Shares of 43,900 Aquestive Therapeutics, Inc. (NASDAQ:AQST)

MONECO Advisors LLC bought a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 43,900 shares of the company’s stock, valued at approximately $156,000.

Several other hedge funds also recently modified their holdings of the company. Financial Advocates Investment Management boosted its stake in shares of Aquestive Therapeutics by 14.7% during the 3rd quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock worth $194,000 after purchasing an additional 5,000 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Aquestive Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock worth $117,000 after acquiring an additional 7,347 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Aquestive Therapeutics by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock worth $1,014,000 after acquiring an additional 9,268 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Aquestive Therapeutics by 713.3% in the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after acquiring an additional 10,700 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after acquiring an additional 13,481 shares during the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Stock Down 5.4 %

Shares of AQST stock opened at $2.80 on Wednesday. The stock has a market cap of $255.30 million, a price-to-earnings ratio of -6.22 and a beta of 2.67. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.24 and a fifty-two week high of $6.23. The firm’s 50 day moving average price is $3.23 and its two-hundred day moving average price is $4.18.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.